Vaxart is actively engaged in developing a robust portfolio of oral tablet vaccines utilizing its proprietary delivery platform. Unlike conventional vaccines that require cold-chain storage and healthcare professionals to administer injections, Vaxart's technology focuses on creating room-temperature stable pills designed to induce mucosal immunity by targeting viral and bacterial diseases directly through the gastrointestinal tract. Their clinical pipeline includes oral tablet vaccine candidates targeting infectious diseases such as norovirus, seasonal influenza, and coronavirus variants, offering significant logistical advantages for global public health distribution.